Full Text View
Tabular View
No Study Results Posted
Related Studies
Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor
This study has been terminated.
Study NCT01001221   Information provided by Sanofi

First Received on October 23, 2009.   Last Updated on September 24, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Neoplasms, Malignant
Additional conditions recognized in this trial
Neoplasms
Interventions listed in this trial
cabazitaxel (XRP6258)
gemcitabine
midazolam
More general drug interventions related to this trial
Adjuvants, Anesthesia
Anesthetics
Anesthetics, General
Anesthetics, Intravenous
Anti-Anxiety Agents
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Central Nervous System Agents
Central Nervous System Depressants
Enzyme Inhibitors
GABA Agents
GABA Modulators
Hypnotics and Sedatives
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
Sanofi


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services